Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...

Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Chipmaker Nvidia will invest $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm's artificial intelligence models for drug discovery. Salt Lake City, Utah-based ...

Recursion Pharmaceuticals (RXRX) has been on a downward spiral lately with significant selling pressure. After declining 26.4% over the past four weeks, the stock looks well positioned for a trend ...

After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next ...

Recursion Pharmaceuticals stock soared as much as 121% on Wednesday after it received an investment from Nvidia. Nvidia said it would invest $50 million in the company as it works to use AI for drug ...